Title: Identification and validation of a lenvatinib resistance-related prognostic signature in
HCC, in which PFKFB4 contributes to tumor progression and lenvatinib resistance
Version: 5 Date: 23 Mar 2025
Reviewer:  Mohamed H. Zidan
Reviewer's report:
Dear Authors,
Re: Revised manuscript entitled "Identification and validation of a lenvatinib resistance-related
prognostic signature in HCC, in which PFKFB4 contributes to tumor progression and lenvatinib
resistance"
Thank you for submitting the revised version of your manuscript. The study presents a
comprehensive and well-executed analysis of lenvatinib resistance in hepatocellular carcinoma,
integrating bioinformatics, prognostic modeling, and experimental validation. The revisions
have improved the clarity and scientific value of the work.
There are two minor points that still warrant attention. First, terminology such as "high-risk"
and "low-risk" is used before the prognostic model is formally introduced; defining these
terms clearly at their first mention would enhance clarity. Second, while the integration of
supplementary figures has been handled appropriately, figure references (e.g., Figure 1H, Figure
10) should be checked for consistency between the text and captions.
With these minor adjustments, the revised manuscript is suitable for publication.
Sincerely,
Title: Identification and validation of a lenvatinib resistance-related prognostic signature in
HCC, in which PFKFB4 contributes to tumor progression and lenvatinib resistance
Version: 5 Date: 23 Mar 2025
Reviewer:  Mohamed H. Zidan
Reviewer's report:
Dear Authors,
Re: Revised manuscript entitled "Identification and validation of a lenvatinib resistance-related
prognostic signature in HCC, in which PFKFB4 contributes to tumor progression and lenvatinib
resistance"
Thank you for submitting the revised version of your manuscript. The study presents a
comprehensive and well-executed analysis of lenvatinib resistance in hepatocellular carcinoma,
integrating bioinformatics, prognostic modeling, and experimental validation. The revisions
have improved the clarity and scientific value of the work.
There are two minor points that still warrant attention. First, terminology such as "high-risk"
and "low-risk" is used before the prognostic model is formally introduced; defining these
terms clearly at their first mention would enhance clarity. Second, while the integration of
supplementary figures has been handled appropriately, figure references (e.g., Figure 1H, Figure
10) should be checked for consistency between the text and captions.
With these minor adjustments, the revised manuscript is suitable for publication.
Sincerely,
Please review this paper.
user
Title: Identification and validation of a lenvatinib resistance-related prognostic signature in
HCC, in which PFKFB4 contributes to tumor progression and lenvatinib resistance
Version: 5 Date: 23 Mar 2025
Reviewer:  Mohamed H. Zidan
Reviewer's report:
Dear Authors,
Re: Revised manuscript entitled "Identification and validation of a lenvatinib resistance-related
prognostic signature in HCC, in which PFKFB4 contributes to tumor progression and lenvatinib
resistance"
Thank you for submitting the revised version of your manuscript. The study presents a
comprehensive and well-executed analysis of lenvatinib resistance in hepatocellular carcinoma,
integrating bioinformatics, prognostic modeling, and experimental validation. The revisions
have improved the clarity and scientific value of the work.
There are two minor points that still warrant attention. First, terminology such as "high-risk"
and "low-risk" is used before the prognostic model is formally introduced; defining these
terms clearly at their first mention would enhance clarity. Second, while the integration of
supplementary figures has been handled appropriately, figure references (e.g., Figure 1H, Figure
10) should be checked for consistency between the text and captions.
With these minor adjustments, the revised manuscript is suitable for publication.
Sincerely,
assistant